DSIP nasal spray, injected DSIP and oral DSIP are not equivalent forms of administration. Available scientific evidence, absorption barriers, product requirements and expected exposure differ significantly between these routes.
The best available human data regarding delta sleep-inducing peptide (DSIP), also known as emideltide, comes from small historical studies in which the peptide was administered intravenously under the supervision of researchers. Subcutaneous administration of DSIP has been studied in animals, including an experiment concerning sleep in cats, but it has not been confirmed as a treatment method for insomnia in humans.
Intranasal DSIP has also appeared in animal studies, including an experiment regarding stroke in rats. However, there is no published clinical study in humans confirming the effectiveness of the DSIP nasal spray in improving sleep.
Evidence regarding oral DSIP is even more limited. There are no reliable pharmacokinetic or clinical studies in humans showing that a standard DSIP tablet or capsule can survive the digestive process and achieve an effective concentration in the blood or brain.
The route of administration therefore impacts far more than mere convenience. It can alter the amount of peptide absorbed in an intact form, the rate at which exposure is achieved, the tissues that come into contact with the formulation, and the requirements regarding manufacturing and sterility. It also determines whether the results of one study can reasonably be applied to another product.
In this article, we compare the individual routes of administration from a scientific perspective. We do not present injection sites, instructions for preparing the nasal spray, methods of reconstitution, or doses for injection or nasal administration, because there is no approved protocol for the self-administration of DSIP.
In what forms is DSIP available or discussed?
DSIP is available or discussed online in several different forms. However, the mere availability of a specific product does not mean that it has been approved, has confirmed clinical efficacy, or is properly absorbed via a given route.
The most common forms include lyophilised peptide in vials, ready-to-use or compounded nasal sprays, liquid research solutions, tablets, capsules, and multi-ingredient preparations.
Lyophilisation means sublimation drying, that is, freeze-drying. It determines the physical form of the peptide and can facilitate its storage or improve its stability before preparing a solution. However, it does not confirm the identity of the peptide, its purity, sterility, endotoxin level, stability after preparation, or suitability for injection.
The exact structure of the molecule is also significant. Native DSIP is a peptide consisting of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of approximately 848.8 g/mol [1]. DSIP acetate contains an acetate counterion and has a different reported molecular weight.
Phosphorylated DSIP, shortened analogues, KND-related peptides, DSIP fusion constructs, and Deltaran are separate research materials. Results concerning one of these forms cannot be automatically applied to a product labelled simply as „DSIP peptide spray” or „DSIP injection”.
Product descriptions can also lead to misunderstandings. The term „research use only” usually means that the product is not being offered as an authorised medicinal product intended for use in humans. The term „compounded” should refer to the preparation of a product within a legal, regulated pharmacy compounding system, where permitted in a given jurisdiction. It should not be used as a general term for any ready-made preparation sold online.
A professional-looking vial, atomiser bottle or label in themselves do not confirm compliance with the standards required for medicinal products.
There is no DSIP product approved by the FDA or the EMA for the treatment of insomnia or to improve sleep. The FDA’s Substance Register recognises emideltide as a specific chemical substance, but explicitly states that the assignment of a substance identifier does not imply regulatory evaluation or approval [2].
For this reason, commercial forms of DSIP must be clearly distinguished from the forms and routes of administration that have actually been scientifically studied.
DSIP nasal spray and intranasal administration
Intranasal administration of DSIP is a scientifically plausible experimental route of administration, but no clinical study in humans has confirmed that a DSIP nasal spray is an effective or reliably absorbed treatment for sleep problems.
The nasal cavity contains a large area of well-vascularised respiratory tract mucosa and a smaller olfactory region, which has anatomical connections to the central nervous system. Intranasal administration bypasses the gastrointestinal tract and may allow certain substances to enter the bloodstream via the nasal mucosa. In the case of selected molecules, a certain proportion of the substance may also reach brain-related structures via the olfactory region or the trigeminal nerve.
However, this does not mean that every peptide automatically travels from the nose to the brain.
Intranasal absorption is influenced by a number of factors. These include the site of aerosol deposition, the design of the device, droplet size, fluid volume, peptide solubility, pH, osmolality, preservatives, absorption-enhancing substances, the presence of mucus, local enzymes and mucociliary clearance.
A review on the intranasal delivery of peptides found that the bioavailability of peptides administered via this route is often low and highly dependent on the formulation. The authors reported that for many commercially available intranasal peptide products, bioavailability in humans is below 5%, although this value varies depending on the molecule and formulation. Efficacy may be significantly influenced by, amongst other factors, pH, osmolality, solubility, site of deposition, absorption-enhancing substances and mucoadhesive properties [3].
Therefore, the amount of DSIP stated on the aerosol label cannot be equated with the amount that actually reaches the bloodstream or the brain.
The most significant published experiment on intranasal DSIP discussed in this context was carried out on animals, not on humans. In a 2021 study, rats were administered 120 µg/kg of DSIP intranasally approximately one hour before experimentally induced focal cerebral ischaemia, and then for seven days following reperfusion. Faster improvement in motor function was observed in the treated animals; however, the difference in infarct volume was not statistically significant [4].
The study investigated post-stroke recovery in rats and utilised a specific experimental formulation and regimen. It did not assess insomnia, sleep onset, intranasal absorption in humans, safety in humans, or the commercial DSIP aerosol.
This is particularly important in the case of searches such as „DSIP nasal spray for sleep dosage instructions”. The dose administered intranasally in the rat stroke study cannot be extrapolated to a regimen for using the spray before bedtime in humans.
Rats and humans differ in terms of nasal anatomy, mucosal surface area, breathing patterns, metabolism, formulation delivery and scaling relative to body weight. Improvements in motor function following an experimental stroke also do not demonstrate a beneficial effect on sleep.
Online reviews referred to as „DSIP nasal spray reviews” should also be treated with caution if they do not relate to a controlled clinical trial in humans. Individual experiences may depend on expectations, the concurrent use of melatonin or sedatives, changes in sleep habits, differences between products, and natural variations in sleep from night to night.
Such data do not allow us to determine bioavailability or to confirm that the product actually contains the declared amount of DSIP.
DSIP by injection and subcutaneous administration
Injectable DSIP has the best-documented research history; however, data from human studies mainly relate to intravenous administration. These do not support current practices regarding self-administered subcutaneous injections.
Intravenous administration delivers a substance directly into the bloodstream. It is precisely this route that was used in historical studies of sleep in humans.
In a single controlled crossover study, six healthy adults received a slow intravenous infusion of 25 nmol/kg. The researchers reported an immediate increase in sleep pressure and subsequent changes in nocturnal sleep parameters [5].
In another early study, the same body-weight-dependent dose was administered intravenously to six people with chronic insomnia [6]. In subsequent controlled studies of insomnia, 25 nmol/kg administered intravenously was also used. The results included both minor objective changes and effects of little clinical significance, as well as a lack of marked improvement in subjective sleep quality [7,8].
These studies cannot be regarded as evidence of the efficacy of subcutaneous DSIP.
When administered subcutaneously, the substance enters the tissue beneath the skin. It must then travel through the tissues before reaching the local blood vessels or the lymphatic system. Absorption may therefore be slower or incomplete and depends, amongst other factors, on the formulation, the volume administered, tissue perfusion, local enzymes and the stability of the peptide.
Using the same number of micrograms as in the intravenous study does not guarantee that the same concentration or time-course exposure profile will be achieved.
The most direct data on subcutaneous DSIP and sleep come from animal studies. In one experiment, eight cats were administered 120 nmol/kg of DSIP subcutaneously prior to an eight-hour sleep recording. An increase in deep slow-wave sleep and delta activity on the EEG was observed. However, changes in total wakefulness time, total slow-wave sleep, time to fall asleep and REM latency were not statistically significant, and total REM sleep time remained unchanged [9].
Research shows that subcutaneous DSIP can induce measurable biological effects in cats under specific experimental conditions. However, it does not determine the human dose, administration frequency, safety margin, or efficacy in treating insomnia.
Another example is Deltaran, a preparation containing DSIP. Female SHR mice were administered approximately 100 µg/kg subcutaneously for five consecutive days each month, from the age of three months until natural death [10]. The study focused on lifespan and tumour-related processes, not on sleep in humans. Furthermore, a specific preparation containing DSIP was used. This protocol cannot therefore form the basis for an online „DSIP injection cycle” for humans.
Injections also entail additional requirements regarding product quality. A parenteral preparation must be manufactured correctly and tested for sterility, endotoxins, particulate matter, identity, concentration and stability.
Chemical purity is not the same as sterility. For example, a high purity result obtained using the HPLC method does not rule out the presence of microorganisms, endotoxins, abnormal concentrations or unsuitable excipients.
This applies to intravenous, subcutaneous and intramuscular administration, as well as other parenteral routes.
Oral DSIP: tablets, capsules and pills
There is no reliable evidence to show that standard tablets, capsules or other oral forms of DSIP deliver a clinically effective amount of the intact peptide in humans.
Peptides taken orally face two main obstacles.
Firstly, in the stomach and intestines, they are exposed to acid, fluctuating chemical conditions and digestive enzymes, which can break down peptide bonds.
Secondly, even if part of an intact peptide reaches the small intestine, its absorption through the intestinal wall may be limited. Peptides are generally larger, more polar and find it more difficult to pass through cell membranes than conventional small-molecule drugs.
In a peer-reviewed review on the oral delivery of peptides, enzymatic degradation and poor intestinal permeability were identified as some of the main reasons why most peptide drugs cannot simply be administered in a standard tablet or capsule [11].
Evidence suggesting that DSIP can cross the blood-brain barrier model does not mean that it works when swallowed. The gastrointestinal tract and the blood-brain barrier are completely different biological barriers.
For orally administered DSIP to reach the brain, it would first need to remain sufficiently intact during digestion. Next, it would have to cross the intestinal barrier, enter the systemic circulation, avoid excessive degradation, achieve adequate exposure, and ultimately reach the cerebral circulation.
Data concerning the final stage, namely the blood–brain barrier, cannot replace evidence regarding all preceding stages.
Some peptide medicines have been successfully developed in oral form. However, these products typically require molecule-specific formulation technologies, absorption enhancers, protective systems or particular pharmacological properties. Their existence does not prove that a standard DSIP capsule works in the same way.
None of the discussed DSIP studies determine the oral bioavailability, pharmacokinetics, sleep-improving efficacy or safety of conventional tablets, capsules, pills, sublingual lozenges or buccal preparations.
The oral product may also contain substances other than intact DSIP or rely solely on an unverified manufacturer's declaration. Without analytical and clinical studies, the apparent effect may stem from another ingredient, user expectation or natural sleep variability.
The term „oral DSIP supplement” should therefore not be treated as proof that native emideltide reaches the bloodstream or the brain.
Nasal spray DSIP versus injection
Injection can provide more predictable systemic exposure in controlled research settings, whereas nasal administration is non-invasive, but strongly depends on the formulation and device performance. Neither of these routes has been approved as a treatment for insomnia using DSIP.
The difference is more complex than simply stating that the injection is „stronger” and the nasal spray is „easier”.
Intravenous administration bypasses the absorption process and has been used in small historical human sleep studies [5–8]. Subcutaneous administration still requires absorption from the tissues and there are no comparable controlled data regarding insomnia in humans.
Nasasal delivery avoids needles and degradation in the gastrointestinal tract, but no human pharmacokinetic study of DSIP has been conducted to determine how much is absorbed, what proportion reaches the brain, how repeatable the dose delivered by each spray is, and how exposure correlates with sleep effects.
| Route or form | Published data on DSIP | The main problem related to delivery | What has still not been established |
|---|---|---|---|
| Intravenous administration | Small human sleep and insomnia studies, typically 25 nmol/kg under supervision [5–8] | Direct systemic exposure, but requires clinical administration and parenteral material of appropriate quality | Approved dosage for insomnia, long-term safety and broad clinical efficacy |
| Subcutaneous administration | A study of sleep in cats and other animal experiments [9,10] | Absorption from tissues; exposure and stability may differ from intravenous administration | Bioavailability in humans, efficacy on sleep, dosing regimen and equivalence of routes |
| Nasal spray | A study of post-stroke recovery in rats at a dose of 120 µg/kg; no validated sleep study in humans [4] | Variable deposition, mucosal clearance, enzymes, small administration volume and dependence on formulation | Intranasal bioavailability in humans, dose per night, onset of action, safety and advantages over injection |
| A standard tablet or capsule | Lack of reliable clinical bioavailability or sleep efficacy studies | Degradation in the gastrointestinal tract and poor intestinal permeability [11] | Is there significant exposure to intact DSIP |
| Direct administration to the brain or ventricles | Historical animal experiments | It bypasses systemic absorption, but is highly invasive and specific to research | Indications for consumer products for topical, oral and subcutaneous use |
No direct human study has been conducted comparing nasal DSIP aerosol with intravenous or subcutaneous administration. Claims that nasal DSIP acts faster, injection is stronger, or one route requires a specific multiple of the other's dose therefore remain unverified.
Subjective perceptions of how quickly a substance takes effect do not allow us to determine its bioavailability.
How does the route of administration affect the absorption and interpretation of tests?
The route of administration alters pharmacokinetic issues. Results obtained for one route cannot simply be transferred to another without appropriate comparative studies.
For intravenous administration, essentially complete systemic availability is assumed, as the material enters the blood directly.
Subcutaneous bioavailability should be measured relative to intravenous exposure, typically by comparing concentration–time curves.
Intranasal bioavailability also requires validated analytical methods capable of distinguishing intact DSIP from its metabolites or chemically similar substances.
In the case of oral administration, evidence would be needed that the intact peptide actually reaches the systemic circulation after passing through the digestive tract.
DSIP has also been studied in the context of the blood–brain barrier, but these results require cautious interpretation.
In 1982, anaesthetised dogs were administered an intravenous bolus of DSIP or selected analogues at a dose of 100 µg/kg. Subsequently, the researchers detected increased DSIP-like immunoreactivity in the cerebrospinal fluid [12].
Studies in rats have also demonstrated differences in brain penetration between DSIP-related peptides [13]. In an in vitro model using cerebral microvascular endothelial cells, bidirectional, non-saturable transport of DSIP was observed, consistent with limited simple diffusion. The apparent permeability was similar to that of water-soluble markers with limited permeation capacity [14].
The results suggest that, under certain experimental conditions, a certain amount of DSIP or DSIP-related material may cross the blood-brain barrier into the central nervous system. However, they do not indicate how much intact DSIP reaches the human brain following intranasal, subcutaneous or oral administration.
The experiment on dogs used an intravenous bolus, whilst the cell-based model did not fully replicate the physiology of a living human. Older immunological tests may also have detected molecules bound to DSIP or its metabolites, rather than the intact peptide alone.
The formulation can alter exposure even when the route of administration is the same. In the case of intranasal products, factors such as pH, tonicity, viscosity, preservatives, concentration, spray characteristics, droplet distribution and the operation of the device may be significant [3].
In injectable preparations, excipients and peptide aggregation can affect stability and tissue reactions. Tablet coatings, enzyme inhibitors and absorption enhancers, on the other hand, can significantly alter the oral delivery of peptides [11].
Therefore, the mere information that a product is „nasal”, „injectable” or „oral” is not sufficient. Studies should also cover the specific formulation and delivery system.
DSIP injection sites: why search interest outweighs evidence
Information about where to administer DSIP injections is frequently searched for, but this interest stems mainly from online discussions about self-administration rather than clinical trials determining safe administration sites.
In peer-reviewed human sleep studies, DSIP has been administered intravenously under research or clinical supervision [5–8]. The abdomen, thigh, arm or other potential sites of subcutaneous administration have not been compared.
In animal studies, routes and sites of administration appropriate for the species and the specific experimental protocol were used. These methods cannot be translated into instructions for human use.
No controlled study has shown that a specific subcutaneous injection site provides better absorption of DSIP, a stronger effect on sleep, or greater safety in humans.
Specifying a precise injection site would also require assuming that the peptide itself, its concentration, sterility, equipment and intended method of use are appropriate. Such assumptions cannot be made in the case of an unapproved research peptide.
Incorrect parenteral administration may lead to infection, abscesses, tissue damage, dosing errors, vascular or nerve damage, allergic reactions and exposure to contaminated or incorrectly labelled material.
There is therefore no evidence-based site on the body or procedure that can be presented as an established method for self-injection of DSIP. At present, there is no regulatory-approved protocol for self-injection of DSIP, nor is there a preferred site for such injections.
Dosage of DSIP nasal spray and limitations of such information
Claims regarding the dosage of DSIP in a nasal spray are not supported by validated sleep studies in humans. Nor does the stated number of micrograms per spray indicate how much DSIP will be absorbed or reach the brain.
The label of a nasal product may specify the amount per spray, the total amount in the bottle, the concentration of the solution or simply the amount corresponding to the contents of the original vial. These values are not equivalent.
Even if the pump delivers a constant volume of fluid, the actual mass of the substance depends on its concentration and the operation of the device. The amount absorbed then depends on the site of fluid deposition, its runoff or swallowing, mucociliary clearance, the condition of the nasal mucosa, enzymatic degradation, and the properties of the formulation.
The amount that ultimately reaches the brain is a separate issue altogether.
The intranasal dose of 120 µg/kg used in the 2021 rat study should not be presented as a human sleep dose without taking context into account [4]. This was a stroke experiment in which the peptide was administered before vessel occlusion and then for seven days following reperfusion. Neither insomnia nor a commercial nasal spray was investigated.
Simply converting the dose used in rats to a human body weight would not be a valid clinical method.
Internet sources may recommend a specific number of sprays, a particular time before sleep, or the length of a cycle. If such recommendations are not supported by a peer-reviewed human study using the same molecule form, formulation, concentration, device, and intended use, they should be treated as vendor instructions or anecdotal practices rather than independent clinical evidence.
There is also a lack of sufficient published data to determine the shelf life, refrigerated storage time, preservation system or the retention of activity in commercial DSIP aerosols after opening.
Preparing the DSIP aerosol oneself introduces further uncertainties. The correct formulation of a pharmaceutical intranasal product requires monitoring of concentration, pH, osmolality, microbiological quality, the efficacy of the preservative system (if used), packaging compatibility, pump accuracy, the reproducibility of the dispensed dose, peptide stability and nasal mucosal tolerance.
Simply dissolving the freeze-dried peptide in a liquid and placing it in a spray bottle does not confirm any of these parameters.
For this reason, there is no evidence-based home recipe for preparing a DSIP nasal spray.
„Research-only” products versus authorised medicines
The DSIP product, which is intended for research purposes only, is not an authorised medicinal product, regardless of whether it is sold as a nasal spray, an injection vial, a tablet or a capsule.
Approved medicines are assessed in terms of the reproducibility of the manufacturing process, identity, potency, purity, stability, clinical efficacy, safety, labelling and post-marketing safety monitoring for specific routes of administration and indications.
The route of administration forms part of the authorisation process. Data supporting an injectable medicine do not automatically imply authorisation of its intranasal or oral forms. In the case of intranasal products, the performance of the device and the reproducibility of the delivered dose are also important quality factors.
Research substances may have legitimate laboratory applications; however, the term „research grade” is not a clinical regulatory category confirming that the material is suitable for administration to humans.
A certificate attesting to the high purity of the peptide does not replace the sterility and endotoxin tests required for injectable products, the preservative and dose-consistency tests for nasal sprays, or the dissolution and bioavailability tests for oral products.
Geographical search terms, such as „DSIP nasal spray UK”, do not alter the quality of the scientific evidence. The fact that a product is advertised or distributed in the UK does not mean that it has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
Regulatory status and compounding rules may change. Official drug databases and qualified healthcare professionals are therefore a more reliable source of information than commercial product descriptions [15].
FAQ: Methods of submitting a DSIP application
Has the DSIP nasal spray been proven to have an effect on sleep?
No. There is no published human clinical study confirming the efficacy of DSIP nasal spray in treating insomnia or improving sleep quality. The discussed study of intranasal DSIP was conducted on rats after an experimental stroke and was not a human sleep study [4].
Is DSIP in injection form better than a nasal spray?
No direct human study has answered this question. Intravenous DSIP has been investigated in small human sleep studies, whilst there is a lack of comparable data on insomnia for the intranasal and subcutaneous routes. More predictable systemic exposure following intravenous administration does not automatically translate into a better clinical outcome.
Has subcutaneous DSIP been studied in relation to sleep in humans?
The main studies on sleep in humans have involved intravenous administration. In a subcutaneous experiment on cats, an increase in deep slow-wave sleep and delta activity on the EEG was observed, but several other sleep parameters did not change significantly [9]. The results from animal studies do not allow for the establishment of a subcutaneous protocol for humans.
Can DSIP be taken orally?
There are no reliable human data showing that a standard DSIP tablet or capsule delivers an effective amount of intact peptide. Research into peptide delivery shows that gastrointestinal enzymes and poor intestinal permeability pose significant barriers to their oral absorption [11]. A specially developed oral formulation of DSIP would require its own pharmacokinetic and clinical trials.
Does DSIP cross the blood–brain barrier?
Animal studies and in vitro models suggest that a certain amount of DSIP or DSIP-related material may cross the blood–brain or blood–cerebrospinal fluid barriers following systemic exposure [12–14]. However, this does not prove that DSIP is effectively delivered to the human brain following administration via a nasal spray, subcutaneous injection or oral administration.
What is the recommended dose of DSIP nasal spray for sleep?
No validated intranasal dose of DSIP for sleep has been established in humans. Dosages derived from rat experiments, retailers’ websites or user reports should not be presented as clinical guidance. The aerosol concentration, device performance, absorption rate, stability and cerebral exposure for an approved DSIP product for sleep have not been established.
How much DSIP should be injected?
There is no approved DSIP dose for self-injection. Historical human studies used supervised, body-weight-dependent intravenous protocols, rather than modern commercial subcutaneous products. Converting these experimental amounts into a dose for home injection would overlook differences in bioavailability, formulation, purity, sterility and individual risk.
Where should DSIP be injected?
The published evidence does not specify a safe or preferred site for self-injection of DSIP. Human sleep studies have used supervised intravenous administration and have not compared subcutaneous injection sites. There is therefore no evidence-based site for self-injection of DSIP.
Can a nasal spray be prepared from freeze-dried DSIP?
Merely dissolving the material and placing it in a spray bottle does not create a validated nasal medicine. Pharmaceutical nasal products require confirmation of concentration, stability, pH, osmolality, microbiological quality, packaging compatibility, pump accuracy, delivered dose uniformity, and mucosal tolerance. An evidence-based home method for preparing such a product cannot be recommended.
Are DSIP oral capsules safer than injections?
There is not enough data to draw such a conclusion. Oral administration eliminates the risk directly associated with needles, but the product identity, ingredients, gastrointestinal stability, absorption, interactions and clinical safety remain uncertain. Poor absorption may cause a lack of efficacy, whereas improper ingredients or contaminants may pose other risks.
Is the DSIP nasal spray approved in the UK?
Based on the data discussed, DSIP/emideltide is not a UK-approved medicine for insomnia. The mere fact that the product is advertised or shipped within the UK does not confirm MHRA authorisation. As the regulatory status may change, current information should be checked in official sources [15].
Limitations of available data
A direct comparison of different DSIP administration routes is difficult because the peptide has not undergone a modern formulation development programme.
Human sleep studies have mainly used intravenous administration and involved very small groups of participants. The most important data regarding subcutaneous administration in the context of sleep come from an animal experiment, whereas the available intranasal study concerned stroke recovery in rats, not sleep in humans. Furthermore, no clinically significant data regarding standard oral DSIP have been established.
Blood–brain barrier studies do not resolve these limitations. They suggest that under certain conditions of systemic exposure, penetration into the central nervous system may occur, but they do not provide reliable human bioavailability values for individual routes of administration.
Older immunological assays may also detect DSIP-like material, rather than exclusively the intact peptide. Results obtained in dogs, rats, cats or in laboratory cell models cannot be used directly to predict the concentration of intact DSIP in the human brain.
Differences between products constitute another significant limitation. Native DSIP, DSIP acetate, phosphorylated analogues, fusion peptides and combination preparations should not be treated as the same substance.
Commercial products may also differ in their excipients, concentration, delivery devices, storage conditions and quality control. Without independent analytical and clinical data for a specific product, comparisons between routes of administration remain largely experimental or theoretical.
Disclaimer
This article is for educational and scientific-information purposes only. It does not constitute medical advice, dosing instructions, a guide to performing injections, a recipe for preparing a nasal spray, or purchasing advice.
The content must not be used for self-administering or preparing an unapproved peptide. Delta sleep-inducing peptide (DSIP/emideltide) is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of insomnia, sleep improvement, stroke recovery, or any other uses discussed in this article.
Human data are limited and come mainly from controlled intravenous administration experiments. Evidence regarding subcutaneous, intranasal and oral administration is preclinical, absent or remains insufficient.
References
- National Centre for Biotechnology Information. (2026). PubChem compound summary for CID 68816, delta sleep-inducing peptide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/68816
- U.S. Food and Drug Administration. (n.d.). Emideltide: UNII YN28Z5YZ73. Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/yn28z5yz73
- Al Bakri, W., Donovan, M. D., Cueto, M., Wu, Y., Orekie, C., & Yang, Z. (2018). Overview of intranasally delivered peptides: Key considerations for pharmaceutical development. Expert Opinion on Drug Delivery, 15(10), 991–1005. https://doi.org/10.1080/17425247.2018.1517742
- Tukhovskaya, E. A., Ismailova, A. M., Shaykhutdinova, E. R., Slashcheva, G. A., Prudchenko, I. A., Mikhaleva, I. I., Khokhlova, O. N., Murashev, A. N., & Ivanov, V. T. (2021). Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules, 26(17), 5173. https://doi.org/10.3390/molecules26175173
- Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behaviour. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 19(8), 341–345. https://pubmed.ncbi.nlm.nih.gov/6895513/
- Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
- Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
- Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919
- Susić, V. (1987). The effect of subcutaneous administration of delta sleep-inducing peptide (DSIP) on some parameters of sleep in the cat. Physiology & Behavior, 40(5), 569–572. https://doi.org/10.1016/0031-9384(87)90098-9
- Popovich, I. G., Voitenkov, B. O., Anisimov, V. N., Ivanov, V. T., Mikhaleva, I. I., Zabezhinski, M. A., Alimova, I. N., Baturin, D. A., Zavarzina, N. Y., Rosenfeld, S. V., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of ageing, life span and spontaneous tumour incidence in female SHR mice. Mechanisms of Ageing and Development, 124(6), 721–731. https://doi.org/10.1016/S0047-6374(03)00082-4
- Maher, S., Ryan, B., Duffy, A., & Brayden, D. J. (2014). Formulation strategies to improve oral peptide delivery. Pharmaceutical Patent Analyst, 3(3), 313–336. https://doi.org/10.4155/ppa.14.15
- Banks, W. A., Kastin, A. J., & Coy, D. H. (1982). Delta sleep-inducing peptide crosses the blood-brain barrier in dogs: Some correlations with protein binding. Pharmacology Biochemistry and Behavior, 17(5), 1009–1014. https://doi.org/10.1016/0091-3057(82)90486-5
- Kastin, A. J., Banks, W. A., Castellanos, P. F., Nissen, C., & Coy, D. H. (1982). Differential penetration of DSIP peptides into rat brain. Pharmacology Biochemistry and Behavior, 17(6), 1187–1191. https://doi.org/10.1016/0091-3057(82)90118-6
- Raeissi, S., & Audus, K. L. (1989). In-vitro characterisation of blood-brain barrier permeability to delta sleep-inducing peptide. Journal of Pharmacy and Pharmacology, 41(12), 848–852. https://doi.org/10.1111/j.2042-7158.1989.tb06385.x
- Medicines and Healthcare products Regulatory Agency. (2026). Find product information about medicines. GOV.UK. https://www.gov.uk/guidance/find-product-information-about-medicines